Filing Flows › Pelthos Therapeutics (PTHS) › Q1 2026
Pelthos Therapeutics (PTHS) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 14, 2026
Pelthos Therapeutics (PTHS) reported revenue of $10.9M for the first quarter 2026 (Q1 2026) and +16% from the quarter before. Operating margin was -120.0%, net loss $25.1M (229.9% of revenue).
Pelthos Therapeutics, Q1 2026: revenue $10.9M, operating margin -120.0%, net loss $25.1M, operating cash flow −$13.1M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $10.9M | +16% | — |
| Operating profit | −$13.1M | — | — |
| Net earnings | −$25.1M | — | — |
| Operating cash flow | −$13.1M | — | — |
What changed
Revenue was $10.9M in Q1 2026, up 16% from the previous quarter. Net product revenues was the largest line at 98% of revenue.
Operating costs exceeded revenue by $13.1M, an operating margin of -120.0%. The quarter ended with a net loss of $25.1M, wider than the previous quarter's $21.7M loss.
Operating cash flow was −$13.1M. Non-cash charges added back $1.5M of depreciation and amortization and $1.9M of share-based compensation. Working capital and other items added $8.5M. Capital expenditures of $194K exceeded it, leaving free cash flow of −$13.3M.
Questions
What was Pelthos Therapeutics' revenue in the first quarter 2026?
Pelthos Therapeutics (PTHS) reported revenue of $10.9M for the first quarter 2026 (Q1 2026) and +16% from the quarter before.
Was Pelthos Therapeutics profitable in the first quarter 2026?
Operating loss was $13.1M (-120.0% of revenue) and net loss $25.1M.